


Participant flow



Baseline Characteristics

Table 1. Baseline Clinical Characteristics

	Clopidogrel Group (n=90)	Ticagrelor Group (n=88)	P values
Age, yrs	72.7 ± 5.5	71.4 ± 4.9	0.087
Male	60(67.4)	60(73.2)	0.411
BMI, kg/m ²	23.7 ± 3.1	23.7 ± 2.7	0.932
Current smoker	30(33.3)	33(37.5)	0.561
Hypertension	64(71.1)	67(76.1)	0.447
Dislipidemia	17(18.9)	39(33.0)	0.032
Diabetes	22(24.4)	23(26.1)	0.795
Prior stroke	9(10.2)	6(7.4)	0.520
Prior MI	8(8.9)	10(11.4)	0.584
Prior PCI	12(13.3)	17(19.3)	0.280
Medications at discharge			
ACEI/ARB	31(34.4)	35(39.8)	0.462
β-blockers	40(44.4)	40(45.5)	0.892
PPI	87(96.7)	87(98.9)	0.323
Laboratory			
Hemoglobin	130.7 ± 16.2	129.1 ± 16.7	0.491
HCT	38.5 ± 4.4	38.1 ± 4.3	0.600
Creatinine	73.3 ± 17.5	74.5 ± 19.6	0.687
eGFR(mL/(min*1.73m ²))	75.7 ± 22.0	79.1 ± 16.7	0.243

Data are presented as N (%) and mean ± (SD).

Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blocker; BMI, body mass index; eGFR, estimated glomerular filtration rate; HCT, hematokrit; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor.

Table 2. Angiographic and Procedural Characteristics of Treated Lesions

	Clopidogrel Group (n=90)	Ticagrelor Group (n=88)	P values
Total number of lesions treated	1.3 ± 0.8	1.3 ± 0.6	0.553
Target vessel			
Left main trunk	3(3.3)	11(12.5)	0.023
Left anterior descending artery	52(57.8)	64(72.7)	0.036
Left circumflex artery	18(20.0)	23(26.1)	0.331
Right coronary artery	27(30)	23(26.1)	0.566
Vascular access site			
Radial access	86(95.6)	84(95.5)	0.627
Lesion complexity			
Bifurcation lesion	34(37.8)	44(50.5)	0.100
Chronic total occlusion	4(4.4)	1(1.1)	0.191
Several calcification lesions	13(14.4)	15(17.0)	0.634
Lesion treated per patient			
One lesion	59(65.6)	52(59.1)	0.373
Two lesions	18(20.0)	22(25.0)	0.418
More than three lesions	13(14.4)	13(14.8)	0.951
Mean total stent length per lesion	30.6 ± 15.2	39.8 ± 20.3	0.001
Mean stents per lesion	1.2 ± 0.5	1.5 ± 0.7	0.004
Mean stent diameter per lesion	2.8 ± 0.8	3.0 ± 0.5	0.171
Procedural time, min	20.6 ± 12.6	21.0 ± 10.1	0.815
Contrast volume, ml	170.9 ± 57.2	185.3 ± 118.5	0.304

Data are presented as N (%) and mean ± (SD).

Outcome Measures:

Table 3.Outcomes at 3-month and 1-year

	Clopidogrel Group (n=90)	Ticagrelor Group (n=88)	Hazard Ratio (95% CI)	P values
At 3-month follow-up				
MACCE	0	1(1.1)	-	-
All-cause death	0	0	-	-
Bleeding*	1(1.1)	6(6.8)	-	0.05
At 1-year follow-up				
MACCE	6(6.7)	3(3.4)	-	0.357
All cause death	1(1.1)	0(0.0)	-	0.323
Bleeding*	4(4.4)	7(8.0)	-	0.301

Values are n (%), unless otherwise indicated. Data are number of events (Kaplan-Meier estimated event rate), compared by the log-rank test.

Abbreviations: BARC, Bleeding Academic Research Consortium; MACCE, major adverse cardiac and cerebrovascular events.CI = confidence interval; other abbreviations as in Table 1.

* (BARC type 2, 3 or 5)

Adverse events

There were no adverse events associated with this trial.